EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients

Domas Vaitiekus iD, Gintare Muckiene, Dovydas Verikas iD, Audrone Vaitiekiene, Skaiste Astasauskaite, Rolandas Gerbutavicius, Agne Bartnykaite iD, Rasa Ugenskienė, Renaldas Jurkevičius, Elona Juozaitytė iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26094051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Domas Vaitiekus und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania. Hauptthemen laut MEDLINE: Breast Neoplasms, Cardiotoxicity, Polymorphism, Single Nucleotide, Anthracyclines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most common cancer in women worldwide. Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin) are among the most used drugs for the treatment of breast cancer. Unfortunately, anthracyclines cause cardiotoxicity, which is a limiting factor for its use, and the lifetime cumulative dose of anthracyclines is the major risk factor for cardiotoxicity. In our study, we focused on acute and subacute heart damage. One of the main factors is a genetic predisposition, which determines individual susceptibility to anthracycline cardiotoxicity. The main idea of this study was, for the first time, to evaluate drug metabolism-related genes as a risk factor for developing cardiovascular toxicity in breast cancer patients. The main objective of our study was to identify the impact of drug metabolism-related gene SNPs on the development of subclinical heart damage during and/or after doxorubicin-based chemotherapy in breast cancer patients. The data of 81 women with breast cancer treated with doxorubicin-based chemotherapy in an outpatient clinic were analyzed, and SNP RT-PCR tests were performed. The drug metabolism-related gene variants SULT2B1 rs10426377, UGT1A6 rs17863783, CBR1 rs9024, CBR3 rs1056892, NCF4 rs1883112, and CYBA rs1049255 did not reach a statistically important impact on ABCC in multivariate logistic regression analysis. However, we identified that NCF4 rs1883112 had a risk reduction tendency for ABCC (OR = 0.49, 95% CI 0.27–0.87, p = 0.015). Our findings suggest that some SNPs, such as NCF4 rs1883112, may be associated with a reduced risk of cardiotoxicity, while no variants in this study showed a statistically significant increased risk. Even though, NCF4 rs1883112 showed a risk reduction tendency, suggesting the potential for personalized risk stratification. We can conclude that multiple genes are involved in ABCC, with different impacts, and it is unlikely that there is a single driver gene in ABCC pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCardiotoxicityPolymorphism, Single NucleotideAnthracyclinesHumansFemaleMiddle AgedAdultDoxorubicinGenetic Predisposition to DiseaseAgedGlucuronosyltransferaseSulfotransferasesFerredoxin-NADP ReductaseAlcohol Oxidoreductases

Stichwörter der Autor:innen

CBR1 rs9024CBR3 rs1056892CYBA rs1049255NCF4 rs1883112SULT2B1 rs10426377UGT1A6 rs17863783anthracycline cardiotoxicitychemotherapy heart damagedoxorubicin cardiomyopathysubclinical heart damage

Substanzen

AnthracyclinesDoxorubicinCBR3 protein, humanCBR1 protein, humanGlucuronosyltransferaseSulfotransferasesFerredoxin-NADP ReductaseAlcohol Oxidoreductases

Autor:innen und Institutionen

  • Clinic of Oncology and Hematology, Institute of Oncology, Faculty of Medicine, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
  • Clinical Department of Cardiology, Medical Academy, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.
  • Laboratory for Automation of Cardiovascular Investigation, Institute of Cardiology, Lithuanian University of Health Sciences, LT-44307 Kaunas, Lithuania.

ORCID-Profile: Domas Vaitiekus, Dovydas Verikas, Agne Bartnykaite, Elona Juozaitytė

Zitieren

APA

Vaitiekus, D., Muckiene, G., Verikas, D., Vaitiekiene, A., Astasauskaite, S., Gerbutavicius, R., Bartnykaite, A., Ugenskienė, R., Jurkevičius, R., & Juozaitytė, E. (2025). Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26094051

Vancouver

Vaitiekus D, Muckiene G, Verikas D, Vaitiekiene A, Astasauskaite S, Gerbutavicius R, et al. Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26094051

BibTeX
@article{Vaitiekus2025,
  author = {Vaitiekus, Domas and Muckiene, Gintare and Verikas, Dovydas and Vaitiekiene, Audrone and Astasauskaite, Skaiste and Gerbutavicius, Rolandas and Bartnykaite, Agne and Ugenskienė, Rasa and Jurkevičius, Renaldas and Juozaitytė, Elona},
  title = {Drugs Metabolism-Related Genes Variants Impact on Anthracycline-Based Chemotherapy Induced Subclinical Cardiotoxicity in Breast Cancer Patients},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26094051}
}
Kostenlos starten →